Skip to main content
Premium Trial:

Request an Annual Quote

CytoVas, BD Biosciences Developing Dx for Vascular Health

NEW YORK (GenomeWeb News) – CytoVas and BD Biosciences entered into a strategic alliance to develop a blood-based diagnostic test for predicting a patient's risk of heart attack and stroke.

Under the terms of the deal, announced on Thursday by CytoVas, the Philadelphia-based company will investigate the ability of the test, currently called the Vascular Health Profile, to evaluate cardiovascular disease progress. The test will also be assessed for its ability to determine the efficacy and side effects of existing and experimental medicines, CytoVas said. It added that studies aimed at several therapies are underway.

It and BD Biosciences, a division of Becton Dickinson, expect the alliance to last two years, after which they will consider options to obtain regulatory approval and reimbursement for the test.

Atherosclerotic cardiovascular disease affects more than 82 million people in the US and is the leading cause of death in the developed world, CytoVas noted. Nonetheless, there are no reliable predictive measures that allow physicians to stratify an individual's risk of developing the disease and then to optimize treatment and management of the disease.

"I believe [the test] will become instrumental in guiding treatment decisions by helping us understand what is happening, in real time, at the actual site of a patient's atherosclerotic plaque," BD Biosciences Worldwide Vice President of Scientific Affairs Noel Warner said in a statement. "This could be instrumental in guiding clinical treatment as well as aiding industry as a biomarker or companion diagnostic for therapeutic innovation."

CytoVas is a biomarker discovery and development firm founded under the University of Pennsylvania Upstart incubator program by Emile Mohler, Jonni Moore, and Wade Rogers from the Perelman School of Medicine at the University of Pennsylvania. Its Cytometric Fingerprinting technology automates pattern recognition of known cellular biomarkers of disease and treatment, it said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.